[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2019 Future of Cancer related Pain R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

February 2019 | 110 pages | ID: 2A39EE18E84EN
VPAResearch

US$ 1,979.00 US$ 2,199.00 -10 %
Offer valid until December 31, 2024!

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global demand for Cancer related Pain treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Cancer related Pain pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Cancer related Pain pipeline companies from advancing their products into Phase 3 or Phase 4.

Cancer related Pain Report Description-

The 2019 pipeline study on Cancer related Pain pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Cancer related Pain pipeline compounds.

The Cancer related Pain pipeline guide presents information on all active drugs currently being developed for Cancer related Pain. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Cancer related Pain pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Cancer related Pain drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Cancer related Pain product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Cancer related Pain pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Cancer related Pain pipeline report includes-
  • An overview of Cancer related Pain disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of Cancer related Pain pipeline
  • Company wise list of Cancer related Pain pipeline
  • Mechanism of Action wise Cancer related Pain pipeline
    • For each pipeline candidate, the following details are provided
    • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
    • Current status of development
    • Drug overview
    • Mechanism of Action
    • Pre-clinical and Clinical Trials/Results
  • Company Overview and Recent Developments
REASONS TO BUY
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Cancer related Pain pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Cancer related Pain pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into companies participating in Cancer related Pain pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL CANCER RELATED PAIN PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. EXECUTIVE SUMMARY

3.1 Cancer related Pain Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
  3.2.1 Pre-clinical
  3.2.2 Discovery
  3.2.3 Phase
  3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
  3.3.1 Phase
  3.3.2 Pre-registration
3.4 Companies involved in Cancer related Pain pipeline, H1- 2019
3.5 Mechanism of Action wise Cancer related Pain Pipeline Candidates

4 ALEXZA PHARMACEUTICALS INC CANCER RELATED PAIN PIPELINE DETAILS

4.1 Alexza Pharmaceuticals Inc Business Profile
4.2 Alexza Pharmaceuticals Inc Cancer related Pain Drug Details
4.3 Drug Snapshot
  4.3.1 Originator
  4.3.2 Collaborator/Co-Developer
  4.3.3 Route of Administration
  4.3.4 Orphan Drug/Fast Track/Special Designation
  4.3.5 Geography
  4.3.6 Type of Molecular Entity
  4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 ANGIOCHEM INC CANCER RELATED PAIN PIPELINE DETAILS

5.1 AngioChem Inc Business Profile
5.2 AngioChem Inc Cancer related Pain Drug Details
5.3 Drug Snapshot
  5.3.1 Originator
  5.3.2 Collaborator/Co-Developer
  5.3.3 Route of Administration
  5.3.4 Orphan Drug/Fast Track/Special Designation
  5.3.5 Geography
  5.3.6 Type of Molecular Entity
  5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 AOXING PHARMACEUTICAL COMPANY INC CANCER RELATED PAIN PIPELINE DETAILS

6.1 Aoxing Pharmaceutical Company Inc Business Profile
6.2 Aoxing Pharmaceutical Company Inc Cancer related Pain Drug Details
6.3 Drug Snapshot
  6.3.1 Originator
  6.3.2 Collaborator/Co-Developer
  6.3.3 Route of Administration
  6.3.4 Orphan Drug/Fast Track/Special Designation
  6.3.5 Geography
  6.3.6 Type of Molecular Entity
  6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 APHIOS CORP CANCER RELATED PAIN PIPELINE DETAILS

7.1 Aphios Corp Business Profile
7.2 Aphios Corp Cancer related Pain Drug Details
7.3 Drug Snapshot
  7.3.1 Originator
  7.3.2 Collaborator/Co-Developer
  7.3.3 Route of Administration
  7.3.4 Orphan Drug/Fast Track/Special Designation
  7.3.5 Geography
  7.3.6 Type of Molecular Entity
  7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 AQUILUS PHARMACEUTICALS INC CANCER RELATED PAIN PIPELINE DETAILS

8.1 Aquilus Pharmaceuticals Inc Business Profile
8.2 Aquilus Pharmaceuticals Inc Cancer related Pain Drug Details
8.3 Drug Snapshot
  8.3.1 Originator
  8.3.2 Collaborator/Co-Developer
  8.3.3 Route of Administration
  8.3.4 Orphan Drug/Fast Track/Special Designation
  8.3.5 Geography
  8.3.6 Type of Molecular Entity
  8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 ASTRAZENECA PLC CANCER RELATED PAIN PIPELINE DETAILS

9.1 AstraZeneca Plc Business Profile
9.2 AstraZeneca Plc Cancer related Pain Drug Details
9.3 Drug Snapshot
  9.3.1 Originator
  9.3.2 Collaborator/Co-Developer
  9.3.3 Route of Administration
  9.3.4 Orphan Drug/Fast Track/Special Designation
  9.3.5 Geography
  9.3.6 Type of Molecular Entity
  9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 CONCENTRIC ANALGESICS INC CANCER RELATED PAIN PIPELINE DETAILS

10.1 Concentric Analgesics Inc Business Profile
10.2 Concentric Analgesics Inc Cancer related Pain Drug Details
10.3 Drug Snapshot
  10.3.1 Originator
  10.3.2 Collaborator/Co-Developer
  10.3.3 Route of Administration
  10.3.4 Orphan Drug/Fast Track/Special Designation
  10.3.5 Geography
  10.3.6 Type of Molecular Entity
  10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 DAEWOONG PHARMACEUTICAL CO LTD CANCER RELATED PAIN PIPELINE DETAILS

11.1 Daewoong Pharmaceutical Co Ltd Business Profile
11.2 Daewoong Pharmaceutical Co Ltd Cancer related Pain Drug Details
11.3 Drug Snapshot
  11.3.1 Originator
  11.3.2 Collaborator/Co-Developer
  11.3.3 Route of Administration
  11.3.4 Orphan Drug/Fast Track/Special Designation
  11.3.5 Geography
  11.3.6 Type of Molecular Entity
  11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 DOMPE FARMACEUTICI SPA CANCER RELATED PAIN PIPELINE DETAILS

12.1 Dompe Farmaceutici SpA Business Profile
12.2 Dompe Farmaceutici SpA Cancer related Pain Drug Details
12.3 Drug Snapshot
  12.3.1 Originator
  12.3.2 Collaborator/Co-Developer
  12.3.3 Route of Administration
  12.3.4 Orphan Drug/Fast Track/Special Designation
  12.3.5 Geography
  12.3.6 Type of Molecular Entity
  12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 FUJIMOTO PHARMACEUTICAL CORP CANCER RELATED PAIN PIPELINE DETAILS

13.1 Fujimoto Pharmaceutical Corp Business Profile
13.2 Fujimoto Pharmaceutical Corp Cancer related Pain Drug Details
13.3 Drug Snapshot
  13.3.1 Originator
  13.3.2 Collaborator/Co-Developer
  13.3.3 Route of Administration
  13.3.4 Orphan Drug/Fast Track/Special Designation
  13.3.5 Geography
  13.3.6 Type of Molecular Entity
  13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 HISAMITSU PHARMACEUTICAL CO INC CANCER RELATED PAIN PIPELINE DETAILS

14.1 Hisamitsu Pharmaceutical Co Inc Business Profile
14.2 Hisamitsu Pharmaceutical Co Inc Cancer related Pain Drug Details
14.3 Drug Snapshot
  14.3.1 Originator
  14.3.2 Collaborator/Co-Developer
  14.3.3 Route of Administration
  14.3.4 Orphan Drug/Fast Track/Special Designation
  14.3.5 Geography
  14.3.6 Type of Molecular Entity
  14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15 IMMUPHARMA PLC CANCER RELATED PAIN PIPELINE DETAILS

15.1 Immupharma Plc Business Profile
15.2 Immupharma Plc Cancer related Pain Drug Details
15.3 Drug Snapshot
  15.3.1 Originator
  15.3.2 Collaborator/Co-Developer
  15.3.3 Route of Administration
  15.3.4 Orphan Drug/Fast Track/Special Designation
  15.3.5 Geography
  15.3.6 Type of Molecular Entity
  15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16 INDIA GLOBALIZATION CAPITAL CANCER RELATED PAIN PIPELINE DETAILS

16.1 India Globalization Capital Business Profile
16.2 India Globalization Capital Cancer related Pain Drug Details
16.3 Drug Snapshot
  16.3.1 Originator
  16.3.2 Collaborator/Co-Developer
  16.3.3 Route of Administration
  16.3.4 Orphan Drug/Fast Track/Special Designation
  16.3.5 Geography
  16.3.6 Type of Molecular Entity
  16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17 KLARIA PHARMA HOLDING AB CANCER RELATED PAIN PIPELINE DETAILS

17.1 Klaria Pharma Holding AB Business Profile
17.2 Klaria Pharma Holding AB Cancer related Pain Drug Details
17.3 Drug Snapshot
  17.3.1 Originator
  17.3.2 Collaborator/Co-Developer
  17.3.3 Route of Administration
  17.3.4 Orphan Drug/Fast Track/Special Designation
  17.3.5 Geography
  17.3.6 Type of Molecular Entity
  17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18 KOMIPHARM INTERNATIONAL CO LTD CANCER RELATED PAIN PIPELINE DETAILS

18.1 Komipharm International Co Ltd Business Profile
18.2 Komipharm International Co Ltd Cancer related Pain Drug Details
18.3 Drug Snapshot
  18.3.1 Originator
  18.3.2 Collaborator/Co-Developer
  18.3.3 Route of Administration
  18.3.4 Orphan Drug/Fast Track/Special Designation
  18.3.5 Geography
  18.3.6 Type of Molecular Entity
  18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19 MEDLAB CLINICAL LTD CANCER RELATED PAIN PIPELINE DETAILS

19.1 Medlab Clinical Ltd Business Profile
19.2 Medlab Clinical Ltd Cancer related Pain Drug Details
19.3 Drug Snapshot
  19.3.1 Originator
  19.3.2 Collaborator/Co-Developer
  19.3.3 Route of Administration
  19.3.4 Orphan Drug/Fast Track/Special Designation
  19.3.5 Geography
  19.3.6 Type of Molecular Entity
  19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments

20 NANOMERICS LTD CANCER RELATED PAIN PIPELINE DETAILS

20.1 Nanomerics Ltd Business Profile
20.2 Nanomerics Ltd Cancer related Pain Drug Details
20.3 Drug Snapshot
  20.3.1 Originator
  20.3.2 Collaborator/Co-Developer
  20.3.3 Route of Administration
  20.3.4 Orphan Drug/Fast Track/Special Designation
  20.3.5 Geography
  20.3.6 Type of Molecular Entity
  20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments

21 NEUROCENTRX PHARMA LTD CANCER RELATED PAIN PIPELINE DETAILS

21.1 Neurocentrx Pharma Ltd Business Profile
21.2 Neurocentrx Pharma Ltd Cancer related Pain Drug Details
21.3 Drug Snapshot
  21.3.1 Originator
  21.3.2 Collaborator/Co-Developer
  21.3.3 Route of Administration
  21.3.4 Orphan Drug/Fast Track/Special Designation
  21.3.5 Geography
  21.3.6 Type of Molecular Entity
  21.3.7 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments

22 NIPPON ZOKI PHARMACEUTICAL CO LTD CANCER RELATED PAIN PIPELINE DETAILS

22.1 Nippon Zoki Pharmaceutical Co Ltd Business Profile
22.2 Nippon Zoki Pharmaceutical Co Ltd Cancer related Pain Drug Details
22.3 Drug Snapshot
  22.3.1 Originator
  22.3.2 Collaborator/Co-Developer
  22.3.3 Route of Administration
  22.3.4 Orphan Drug/Fast Track/Special Designation
  22.3.5 Geography
  22.3.6 Type of Molecular Entity
  22.3.7 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments

23 OBLIQUE THERAPEUTICS AB CANCER RELATED PAIN PIPELINE DETAILS

23.1 Oblique Therapeutics AB Business Profile
23.2 Oblique Therapeutics AB Cancer related Pain Drug Details
23.3 Drug Snapshot
  23.3.1 Originator
  23.3.2 Collaborator/Co-Developer
  23.3.3 Route of Administration
  23.3.4 Orphan Drug/Fast Track/Special Designation
  23.3.5 Geography
  23.3.6 Type of Molecular Entity
  23.3.7 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments

24 ORION CORP CANCER RELATED PAIN PIPELINE DETAILS

24.1 Orion Corp Business Profile
24.2 Orion Corp Cancer related Pain Drug Details
24.3 Drug Snapshot
  24.3.1 Originator
  24.3.2 Collaborator/Co-Developer
  24.3.3 Route of Administration
  24.3.4 Orphan Drug/Fast Track/Special Designation
  24.3.5 Geography
  24.3.6 Type of Molecular Entity
  24.3.7 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments

25 PFIZER INC CANCER RELATED PAIN PIPELINE DETAILS

25.1 Pfizer Inc Business Profile
25.2 Pfizer Inc Cancer related Pain Drug Details
25.3 Drug Snapshot
  25.3.1 Originator
  25.3.2 Collaborator/Co-Developer
  25.3.3 Route of Administration
  25.3.4 Orphan Drug/Fast Track/Special Designation
  25.3.5 Geography
  25.3.6 Type of Molecular Entity
  25.3.7 Current Status
25.4 Drug Overview
25.5 Drug Mechanism of Action
25.6 Clinical/Pre-clinical Trial Details
25.7 Latest Drug Developments

26 PHARMALEADS SA CANCER RELATED PAIN PIPELINE DETAILS

26.1 Pharmaleads SA Business Profile
26.2 Pharmaleads SA Cancer related Pain Drug Details
26.3 Drug Snapshot
  26.3.1 Originator
  26.3.2 Collaborator/Co-Developer
  26.3.3 Route of Administration
  26.3.4 Orphan Drug/Fast Track/Special Designation
  26.3.5 Geography
  26.3.6 Type of Molecular Entity
  26.3.7 Current Status
26.4 Drug Overview
26.5 Drug Mechanism of Action
26.6 Clinical/Pre-clinical Trial Details
26.7 Latest Drug Developments

27 PLEXXIKON INC CANCER RELATED PAIN PIPELINE DETAILS

27.1 Plexxikon Inc Business Profile
27.2 Plexxikon Inc Cancer related Pain Drug Details
27.3 Drug Snapshot
  27.3.1 Originator
  27.3.2 Collaborator/Co-Developer
  27.3.3 Route of Administration
  27.3.4 Orphan Drug/Fast Track/Special Designation
  27.3.5 Geography
  27.3.6 Type of Molecular Entity
  27.3.7 Current Status
27.4 Drug Overview
27.5 Drug Mechanism of Action
27.6 Clinical/Pre-clinical Trial Details
27.7 Latest Drug Developments

28 RECORDATI SPA CANCER RELATED PAIN PIPELINE DETAILS

28.1 Recordati SpA Business Profile
28.2 Recordati SpA Cancer related Pain Drug Details
28.3 Drug Snapshot
  28.3.1 Originator
  28.3.2 Collaborator/Co-Developer
  28.3.3 Route of Administration
  28.3.4 Orphan Drug/Fast Track/Special Designation
  28.3.5 Geography
  28.3.6 Type of Molecular Entity
  28.3.7 Current Status
28.4 Drug Overview
28.5 Drug Mechanism of Action
28.6 Clinical/Pre-clinical Trial Details
28.7 Latest Drug Developments

29 RIBOMIC INC CANCER RELATED PAIN PIPELINE DETAILS

29.1 Ribomic Inc Business Profile
29.2 Ribomic Inc Cancer related Pain Drug Details
29.3 Drug Snapshot
  29.3.1 Originator
  29.3.2 Collaborator/Co-Developer
  29.3.3 Route of Administration
  29.3.4 Orphan Drug/Fast Track/Special Designation
  29.3.5 Geography
  29.3.6 Type of Molecular Entity
  29.3.7 Current Status
29.4 Drug Overview
29.5 Drug Mechanism of Action
29.6 Clinical/Pre-clinical Trial Details
29.7 Latest Drug Developments

30 SEDOR PHARMACEUTICALS LLC CANCER RELATED PAIN PIPELINE DETAILS

30.1 Sedor Pharmaceuticals LLC Business Profile
30.2 Sedor Pharmaceuticals LLC Cancer related Pain Drug Details
30.3 Drug Snapshot
  30.3.1 Originator
  30.3.2 Collaborator/Co-Developer
  30.3.3 Route of Administration
  30.3.4 Orphan Drug/Fast Track/Special Designation
  30.3.5 Geography
  30.3.6 Type of Molecular Entity
  30.3.7 Current Status
30.4 Drug Overview
30.5 Drug Mechanism of Action
30.6 Clinical/Pre-clinical Trial Details
30.7 Latest Drug Developments

31 SORRENTO THERAPEUTICS INC CANCER RELATED PAIN PIPELINE DETAILS

31.1 Sorrento Therapeutics Inc Business Profile
31.2 Sorrento Therapeutics Inc Cancer related Pain Drug Details
31.3 Drug Snapshot
  31.3.1 Originator
  31.3.2 Collaborator/Co-Developer
  31.3.3 Route of Administration
  31.3.4 Orphan Drug/Fast Track/Special Designation
  31.3.5 Geography
  31.3.6 Type of Molecular Entity
  31.3.7 Current Status
31.4 Drug Overview
31.5 Drug Mechanism of Action
31.6 Clinical/Pre-clinical Trial Details
31.7 Latest Drug Developments

32 TETRA BIO-PHARMA INC CANCER RELATED PAIN PIPELINE DETAILS

32.1 Tetra Bio-Pharma Inc Business Profile
32.2 Tetra Bio-Pharma Inc Cancer related Pain Drug Details
32.3 Drug Snapshot
  32.3.1 Originator
  32.3.2 Collaborator/Co-Developer
  32.3.3 Route of Administration
  32.3.4 Orphan Drug/Fast Track/Special Designation
  32.3.5 Geography
  32.3.6 Type of Molecular Entity
  32.3.7 Current Status
32.4 Drug Overview
32.5 Drug Mechanism of Action
32.6 Clinical/Pre-clinical Trial Details
32.7 Latest Drug Developments

33 VIROBAY INC CANCER RELATED PAIN PIPELINE DETAILS

33.1 Virobay Inc Business Profile
33.2 Virobay Inc Cancer related Pain Drug Details
33.3 Drug Snapshot
  33.3.1 Originator
  33.3.2 Collaborator/Co-Developer
  33.3.3 Route of Administration
  33.3.4 Orphan Drug/Fast Track/Special Designation
  33.3.5 Geography
  33.3.6 Type of Molecular Entity
  33.3.7 Current Status
33.4 Drug Overview
33.5 Drug Mechanism of Action
33.6 Clinical/Pre-clinical Trial Details
33.7 Latest Drug Developments

34 WEX PHARMACEUTICALS INC CANCER RELATED PAIN PIPELINE DETAILS

34.1 WEX Pharmaceuticals Inc Business Profile
34.2 WEX Pharmaceuticals Inc Cancer related Pain Drug Details
34.3 Drug Snapshot
  34.3.1 Originator
  34.3.2 Collaborator/Co-Developer
  34.3.3 Route of Administration
  34.3.4 Orphan Drug/Fast Track/Special Designation
  34.3.5 Geography
  34.3.6 Type of Molecular Entity
  34.3.7 Current Status
34.4 Drug Overview
34.5 Drug Mechanism of Action
34.6 Clinical/Pre-clinical Trial Details
34.7 Latest Drug Developments

35. LATEST CANCER RELATED PAIN DRUG PIPELINE DEVELOPMENTS, 2019

36. APPENDIX

36.1 About Us
36.2 Sources and Methodology
36.3 Contact Information


More Publications